Renal Cell Carcinoma

Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products.

What is Renal Cell Carcinoma?

Renal cell carcinoma, also called hypernephroma, is a cancer of the kidneys that forms in the proximal convoluted tubule. In the UK, it is the eighth most common cancer among adults, affecting 9,300 people every year.

Renal Cell Carcinoma Epidemiology

Renal Cell Carcinoma Symptoms

Renal Cell Carcinoma Diagnosis

Renal Cell Carcinoma Risk Factors

Renal Cell Carcinoma Treatments

Renal Cell Carcinoma Survival Rate

Metastatic Renal Cell Carcinoma

Adjuvant Therapy in Renal Cell Carcinoma

Latest Renal Cell Carcinoma News and Research

New review examines link between HDLC and different types of cancer

Researchers summarized studies on the association between high-density lipoprotein cholesterol and different types of cancer

29 Mar 2023

Predicting the likelihood of kidney cancer recurrence by looking at DNA mutations

A decade-long international study into kidney cancer has shown that doctors can predict the likelihood of a patient's disease returning by looking at DNA mutations in their tumors.

24 Feb 2023

DNA sequencing may help predict a patient’s risk of kidney cancer recurrence

Studying the mutations in kidney cancer after surgery could help to better predict the risk of the disease coming back, according to the latest results of a decade-long international study.

23 Feb 2023

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib.

From Ipsen 14 Feb 2023

Recent therapeutic strategies for renal cell carcinoma and the effects of the tumor microenvironment on systemic therapy

Researchers explored the association between the human microbiome and improved renal cell carcinoma outcomes.

6 Feb 2023

Two Cents' Worth: Shared decision making in renal cell carcinoma (RCC)

In this interview, we speak to Steve Pointon, patient advocate in remission from RCC, and Dr Harm van Melick, Consultant Urologist, about their experiences with shared decision-making and the impact it can have on people living with renal cell carcinoma (RCC).

From Ipsen 15 Dec 2022

Cryoablation is more effective than heat-based treatment for some small kidney cancers

For patients with early-stage renal cell carcinomas (RCCs) that measure between 3 and 4 centimeters, a procedure that destroys the cancer by freezing – called cryoablation – yields a lower-risk of cancer-related death compared to heat-based thermal ablation, reports a preliminary study in The Journal of Urology®, an Official Journal of the American Urological Association.

29 Nov 2022

Triplet therapy slows progression of advanced kidney cancer

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.

8 Sep 2022

Study contributes to better understanding of the changes in kinase activity in renal cell carcinoma

A new research paper was published in Oncotarget on August 4, 2022, entitled, "Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors."

17 Aug 2022

Study uncovers how common genetic mutations cause renal cancer

The understanding of the link between common genetic mutations and certain cancers is increasing.

9 Aug 2022

Cytokine-based cancer immunotherapy: current progress and future prospects

In this interview, News-Medical talks to Dr. Shuang Zhou about cytokine-base cancer immunotherapy, the current state of the field, and future prospects.

From Sino Biological Inc. 18 Jul 2022

Moffitt researchers discover kidney cancer-specific splicing variant biomarkers

Kidney cancer accounts for only 4% of all cancers in the United States; however, its incidence has more than doubled since 1975, with the most common type being clear cell renal cell carcinoma.

8 Jul 2022

Moffitt researchers discover how YAP1 protein contributes to angiogenesis in cancers

The formation of new blood vessels, also known as angiogenesis, is critical to the development and progression of cancer.

8 Jul 2022

Study uncovers novel treatment for chromophobe renal cell carcinoma

Chromophobe renal cell carcinoma (ChRCC) is a rare form of kidney cancer for which there are currently no proven treatments for metastatic or unresectable disease.

20 Jun 2022

Conceptual framework to examine the patterns of copy number alterations in human cancer

A new study published in Nature presented a conceptual framework to examine the patterns of copy number alterations in human cancer.

17 Jun 2022

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

In a study of patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning (recurrence-free survival, or RFS) than those who did not take everolimus, although the results narrowly missed the clinical trial's prespecified level for statistical significance.

4 Jun 2022

Researchers illuminate the molecular landscape and clinical features of rare kidney cancer

Translocation renal cell carcinoma (tRCC) is a rare and aggressive form of kidney cancer. It accounts for about 5 percent of all renal cell carcinomas in adults and about 50 percent in children.

10 Jan 2022

Indication of minor added benefit of nivolumab for adjuvant treatment of esophageal cancer

In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care investigated whether nivolumab has an added benefit over watchful waiting in the adjuvant treatment of adults with carcinoma of the esophagus or the gastroesophageal junction and pathological residual disease after prior neoadjuvant chemoradiotherapy (CRT).

10 Dec 2021

SPORE-funded Kidney Cancer Program at UT Southwestern reports wide array of tumor models to date

Funded by a Specialized Program of Research Excellence award from the National Cancer Institute (NCI), the Kidney Cancer Program at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center reports the largest and most diverse catalog of kidney cancer tumor models to date.

29 Nov 2021

Immune checkpoint inhibitor therapy results in longer treatment-free survival for patients with advanced renal cell carcinoma

Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial.

10 Nov 2021

Renal Cell Carcinoma

Overview

Renal Cell Carcinoma Epidemiology

Renal Cell Carcinoma Symptoms

Renal Cell Carcinoma Diagnosis

Feature Articles

Renal Cell Carcinoma Risk Factors

Renal Cell Carcinoma Treatments

Renal Cell Carcinoma Survival Rate

Metastatic Renal Cell Carcinoma

Adjuvant Therapy in Renal Cell Carcinoma

Latest Renal Cell Carcinoma News and Research

New review examines link between HDLC and different types of cancer

Predicting the likelihood of kidney cancer recurrence by looking at DNA mutations

DNA sequencing may help predict a patient’s risk of kidney cancer recurrence

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Recent therapeutic strategies for renal cell carcinoma and the effects of the tumor microenvironment on systemic therapy

Two Cents' Worth: Shared decision making in renal cell carcinoma (RCC)

Cryoablation is more effective than heat-based treatment for some small kidney cancers

Triplet therapy slows progression of advanced kidney cancer

Study contributes to better understanding of the changes in kinase activity in renal cell carcinoma

Study uncovers how common genetic mutations cause renal cancer

Cytokine-based cancer immunotherapy: current progress and future prospects

Moffitt researchers discover kidney cancer-specific splicing variant biomarkers

Moffitt researchers discover how YAP1 protein contributes to angiogenesis in cancers

Study uncovers novel treatment for chromophobe renal cell carcinoma

Conceptual framework to examine the patterns of copy number alterations in human cancer

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

Researchers illuminate the molecular landscape and clinical features of rare kidney cancer

Indication of minor added benefit of nivolumab for adjuvant treatment of esophageal cancer

SPORE-funded Kidney Cancer Program at UT Southwestern reports wide array of tumor models to date

Immune checkpoint inhibitor therapy results in longer treatment-free survival for patients with advanced renal cell carcinoma

Hasret Altan-Martin

Speeding Up Sample Preparation to Accelerate Analytical Chemistry

Ask the Expert: 7 Questions about Colorectal Cancer & Non-invasive Fecal DNA Testing

Lab Diagnostics and Automation eBook

Renal Cell Carcinoma

Overview

Feature Articles

Renal Cell Carcinoma Risk Factors

Renal Cell Carcinoma Treatments

Renal Cell Carcinoma Survival Rate

Metastatic Renal Cell Carcinoma

Adjuvant Therapy in Renal Cell Carcinoma

Latest Renal Cell Carcinoma News and Research

Hasret Altan-Martin

Speeding Up Sample Preparation to Accelerate Analytical Chemistry

Ask the Expert: 7 Questions about Colorectal Cancer & Non-invasive Fecal DNA Testing

Lab Diagnostics and Automation eBook

Newsletters you may be interested in